PHAT
Price
$12.34
Change
+$0.34 (+2.83%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
851.32M
62 days until earnings call
RGNX
Price
$9.71
Change
+$0.29 (+3.08%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
475.84M
61 days until earnings call
Interact to see
Advertisement

PHAT vs RGNX

Header iconPHAT vs RGNX Comparison
Open Charts PHAT vs RGNXBanner chart's image
Phathom Pharmaceuticals
Price$12.34
Change+$0.34 (+2.83%)
Volume$12.93K
Capitalization851.32M
REGENXBIO
Price$9.71
Change+$0.29 (+3.08%)
Volume$8.74K
Capitalization475.84M
PHAT vs RGNX Comparison Chart in %
Loading...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHAT vs. RGNX commentary
Sep 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAT is a Hold and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 05, 2025
Stock price -- (PHAT: $12.00 vs. RGNX: $9.42)
Brand notoriety: PHAT and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAT: 163% vs. RGNX: 87%
Market capitalization -- PHAT: $851.32M vs. RGNX: $475.84M
PHAT [@Biotechnology] is valued at $851.32M. RGNX’s [@Biotechnology] market capitalization is $475.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.77B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAT’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • PHAT’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAT’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 7 bullish TA indicator(s).

  • PHAT’s TA Score: 4 bullish, 4 bearish.
  • RGNX’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than PHAT.

Price Growth

PHAT (@Biotechnology) experienced а -2.91% price change this week, while RGNX (@Biotechnology) price change was +4.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

PHAT is expected to report earnings on Nov 06, 2025.

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAT($851M) has a higher market cap than RGNX($476M). PHAT YTD gains are higher at: 47.783 vs. RGNX (21.863). RGNX has higher annual earnings (EBITDA): -129.93M vs. PHAT (-256.76M). RGNX has more cash in the bank: 323M vs. PHAT (150M). RGNX has less debt than PHAT: RGNX (77.7M) vs PHAT (206M). RGNX has higher revenues than PHAT: RGNX (156M) vs PHAT (114M).
PHATRGNXPHAT / RGNX
Capitalization851M476M179%
EBITDA-256.76M-129.93M198%
Gain YTD47.78321.863219%
P/E RatioN/AN/A-
Revenue114M156M73%
Total Cash150M323M46%
Total Debt206M77.7M265%
FUNDAMENTALS RATINGS
PHAT vs RGNX: Fundamental Ratings
PHAT
RGNX
OUTLOOK RATING
1..100
826
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3542
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
5048

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (71) in the Biotechnology industry is in the same range as PHAT (77) in the null industry. This means that RGNX’s stock grew similarly to PHAT’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PHAT (100) in the null industry. This means that RGNX’s stock grew similarly to PHAT’s over the last 12 months.

RGNX's SMR Rating (98) in the Biotechnology industry is in the same range as PHAT (100) in the null industry. This means that RGNX’s stock grew similarly to PHAT’s over the last 12 months.

PHAT's Price Growth Rating (35) in the null industry is in the same range as RGNX (42) in the Biotechnology industry. This means that PHAT’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for PHAT (100) in the null industry. This means that RGNX’s stock grew significantly faster than PHAT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHATRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 19 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVRTX27.49N/A
N/A
VY® CBRE Real Estate S2
VDMRX10.45N/A
N/A
Virtus KAR Developing Markets R6
ITRGX69.39N/A
N/A
VY® T. Rowe Price Growth Equity S2
JLVMX21.26N/A
N/A
JPMorgan Large Cap Value R6
AIOCX9.99N/A
N/A
American Century International Opps C

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with TNFA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then TNFA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+1.01%
TNFA - PHAT
39%
Loosely correlated
+3.74%
ATRA - PHAT
36%
Loosely correlated
+1.35%
RGNX - PHAT
36%
Loosely correlated
-4.46%
URGN - PHAT
34%
Loosely correlated
-2.94%
PDSB - PHAT
33%
Poorly correlated
-6.15%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-4.46%
SYRE - RGNX
55%
Loosely correlated
+1.07%
MGNX - RGNX
53%
Loosely correlated
+1.57%
DNLI - RGNX
53%
Loosely correlated
-3.40%
IDYA - RGNX
52%
Loosely correlated
+0.27%
ARWR - RGNX
52%
Loosely correlated
+0.72%
More